Excessive or altered BCR signaling is a major determinant in B cell cancers such as lymphoma and lymphocytic leukemia (Burger and Wiestner, 2018; Young and Staudt, 2013), as well as in autoimmune disorders (Rawlings et al., 2017). This evidence concerns the gene BCR and lymphoid leukemia.